For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...

In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines. Among patients with metastatic urothelial carcinoma — ...

Factors like patient characteristics and disease-related features influence surgical recovery as well as treatment success following therapy with Keytruda (pembrolizumab) and Padcev (enfortumab ...

Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection has been the standard of care for muscle-invasive bladder cancer for decades. The advent of ...

Prostate cancer is among the most common cancers in men and a leading cause of cancer-related deaths. With improved detection and therapies, survival rates have risen, but this progress comes with a ...

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...